Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.69
AMAG's Cash to Debt is ranked lower than
83% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. AMAG: 0.69 )
Ranked among companies with meaningful Cash to Debt only.
AMAG' s 10-Year Cash to Debt Range
Min: 0.29  Med: 10000.00 Max: No Debt
Current: 0.69
Equity to Asset 0.44
AMAG's Equity to Asset is ranked lower than
76% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AMAG: 0.44 )
Ranked among companies with meaningful Equity to Asset only.
AMAG' s 10-Year Equity to Asset Range
Min: 0.33  Med: 0.75 Max: 0.98
Current: 0.44
0.33
0.98
F-Score: 5
Z-Score: 1.61
M-Score: 5.34
WACC vs ROIC
5.03%
22.76%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 31.10
AMAG's Operating margin (%) is ranked higher than
92% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. AMAG: 31.10 )
Ranked among companies with meaningful Operating margin (%) only.
AMAG' s 10-Year Operating margin (%) Range
Min: -18217.46  Med: -130.08 Max: 8.03
Current: 31.1
-18217.46
8.03
Net-margin (%) 65.25
AMAG's Net-margin (%) is ranked higher than
97% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. AMAG: 65.25 )
Ranked among companies with meaningful Net-margin (%) only.
AMAG' s 10-Year Net-margin (%) Range
Min: -15420.63  Med: -124.17 Max: 109.19
Current: 65.25
-15420.63
109.19
ROE (%) 42.66
AMAG's ROE (%) is ranked higher than
97% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. AMAG: 42.66 )
Ranked among companies with meaningful ROE (%) only.
AMAG' s 10-Year ROE (%) Range
Min: -86.79  Med: -21.78 Max: 42.96
Current: 42.66
-86.79
42.96
ROA (%) 17.18
AMAG's ROA (%) is ranked higher than
94% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. AMAG: 17.18 )
Ranked among companies with meaningful ROA (%) only.
AMAG' s 10-Year ROA (%) Range
Min: -67.05  Med: -16.91 Max: 16.42
Current: 17.18
-67.05
16.42
ROC (Joel Greenblatt) (%) 450.97
AMAG's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. AMAG: 450.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AMAG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1009.91  Med: -278.72 Max: 12.16
Current: 450.97
-1009.91
12.16
Revenue Growth (3Y)(%) 19.50
AMAG's Revenue Growth (3Y)(%) is ranked higher than
77% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. AMAG: 19.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AMAG' s 10-Year Revenue Growth (3Y)(%) Range
Min: -31.2  Med: 11.00 Max: 265.9
Current: 19.5
-31.2
265.9
» AMAG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

AMAG Guru Trades in Q3 2014

Jim Simons Sold Out
» More
Q4 2014

AMAG Guru Trades in Q4 2014

Ken Heebner 522,000 sh (New)
Paul Tudor Jones 8,431 sh (New)
» More
Q1 2015

AMAG Guru Trades in Q1 2015

Paul Tudor Jones 38,762 sh (+359.76%)
Ken Heebner 522,000 sh (unchged)
» More
Q2 2015

AMAG Guru Trades in Q2 2015

Joel Greenblatt 510,597 sh (New)
Paul Tudor Jones 139,125 sh (+258.92%)
Ken Heebner 522,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AMAG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 11.37
AMAG's P/E(ttm) is ranked higher than
88% of the 220 Companies
in the Global Biotechnology industry.

( Industry Median: 33.70 vs. AMAG: 11.37 )
Ranked among companies with meaningful P/E(ttm) only.
AMAG' s 10-Year P/E(ttm) Range
Min: 10.74  Med: 12.37 Max: 15.65
Current: 11.37
10.74
15.65
Forward P/E 8.38
AMAG's Forward P/E is ranked higher than
89% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 23.42 vs. AMAG: 8.38 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 12.60
AMAG's PE(NRI) is ranked higher than
88% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 33.30 vs. AMAG: 12.60 )
Ranked among companies with meaningful PE(NRI) only.
AMAG' s 10-Year PE(NRI) Range
Min: 10.73  Med: 12.54 Max: 15.81
Current: 12.6
10.73
15.81
P/B 2.61
AMAG's P/B is ranked higher than
65% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. AMAG: 2.61 )
Ranked among companies with meaningful P/B only.
AMAG' s 10-Year P/B Range
Min: 1.12  Med: 2.86 Max: 18.97
Current: 2.61
1.12
18.97
P/S 7.23
AMAG's P/S is ranked higher than
55% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. AMAG: 7.23 )
Ranked among companies with meaningful P/S only.
AMAG' s 10-Year P/S Range
Min: 3.62  Med: 19.58 Max: 496.73
Current: 7.23
3.62
496.73
PFCF 25.87
AMAG's PFCF is ranked higher than
70% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 40.25 vs. AMAG: 25.87 )
Ranked among companies with meaningful PFCF only.
AMAG' s 10-Year PFCF Range
Min: 25.51  Med: 40.39 Max: 351.64
Current: 25.87
25.51
351.64
POCF 25.78
AMAG's POCF is ranked higher than
56% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 32.50 vs. AMAG: 25.78 )
Ranked among companies with meaningful POCF only.
AMAG' s 10-Year POCF Range
Min: 25.4  Med: 55.14 Max: 1268.5
Current: 25.78
25.4
1268.5
EV-to-EBIT 22.46
AMAG's EV-to-EBIT is ranked higher than
55% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 26.88 vs. AMAG: 22.46 )
Ranked among companies with meaningful EV-to-EBIT only.
AMAG' s 10-Year EV-to-EBIT Range
Min: -542.7  Med: -7.10 Max: 90.1
Current: 22.46
-542.7
90.1
Current Ratio 1.71
AMAG's Current Ratio is ranked lower than
78% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. AMAG: 1.71 )
Ranked among companies with meaningful Current Ratio only.
AMAG' s 10-Year Current Ratio Range
Min: 1.65  Med: 8.25 Max: 54.4
Current: 1.71
1.65
54.4
Quick Ratio 1.61
AMAG's Quick Ratio is ranked lower than
75% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. AMAG: 1.61 )
Ranked among companies with meaningful Quick Ratio only.
AMAG' s 10-Year Quick Ratio Range
Min: 1.4  Med: 8.04 Max: 54.33
Current: 1.61
1.4
54.33
Days Inventory 200.78
AMAG's Days Inventory is ranked lower than
71% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 122.55 vs. AMAG: 200.78 )
Ranked among companies with meaningful Days Inventory only.
AMAG' s 10-Year Days Inventory Range
Min: 6.05  Med: 430.02 Max: 14478.33
Current: 200.78
6.05
14478.33
Days Sales Outstanding 72.41
AMAG's Days Sales Outstanding is ranked lower than
57% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. AMAG: 72.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMAG' s 10-Year Days Sales Outstanding Range
Min: 4.86  Med: 31.89 Max: 863.25
Current: 72.41
4.86
863.25

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 6.13
AMAG's Price/Projected FCF is ranked lower than
65% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. AMAG: 6.13 )
Ranked among companies with meaningful Price/Projected FCF only.
AMAG' s 10-Year Price/Projected FCF Range
Min: 6.03  Med: 10.40 Max: 96.83
Current: 6.13
6.03
96.83
Price/Median PS Value 0.40
AMAG's Price/Median PS Value is ranked higher than
87% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. AMAG: 0.40 )
Ranked among companies with meaningful Price/Median PS Value only.
AMAG' s 10-Year Price/Median PS Value Range
Min: 0.17  Med: 0.76 Max: 83.13
Current: 0.4
0.17
83.13
Earnings Yield (Greenblatt) (%) 4.42
AMAG's Earnings Yield (Greenblatt) (%) is ranked higher than
87% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. AMAG: 4.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AMAG' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.1  Med: 2.05 Max: 4.42
Current: 4.42
1.1
4.42

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 377 505 599 689
EPS($) 5.20 7.64 7.71 8.74
EPS without NRI($) 5.20 7.64 7.71 8.74

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AMU.Germany,
AMAG Pharmaceuticals Inc is a Delaware corporation was founded in 1981. The Company is a specialty pharmaceutical company that markets Feraheme Injection for Intravenous, or IV, use to treat iron deficiency anemia, or IDA, and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucositis. The Company sells Feraheme to authorized wholesalers and specialty distributors who, in turn, sell Feraheme to healthcare providers who administer Feraheme primarily within hospitals, hematology and oncology centers and nephrology clinics. In addition, it also outsource a number of its product supply chain services to ICS, its third-party logistics provider, including services related to warehousing and inventory management, distribution, chargeback processing, accounts receivable management and customer service call center management. The Company is subject to extensive additional federal, state and foreign healthcare regulation, which includes but is not limited to, the Federal False Claims Act, the Federal Anti-Kickback Statute, the Foreign Corrupt Practices Act, and their state analogues, and similar laws in countries outside of the U.S.
» More Articles for AMAG

Headlines

Articles On GuruFocus.com
AMAG Pharmaceuticals Inc. (AMAG) EVP, CFO David Arkowitz sells 2,705 Shares Feb 28 2011 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2010 
AMAG Pharmaceuticals Inc. (AMAG) President and CEO Brian Jg Pereira sells 230,011 Shares Nov 12 2009 
AMAG Pharmaceuticals Inc. (AMAG) CFO and Chief Business Officer David Arkowitz sells 4,459 Shares Nov 12 2009 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2009 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2009 
AMAG Pharmaceuticals Inc. (AMAG) President and CEO Brian Jg Pereira sells 5,000 Shares Aug 05 2009 

More From Other Websites
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences Sep 01 2015
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences Sep 01 2015
Coverage initiated on AMAG Pharma by Raymond James Sep 01 2015
AMAG Pharmaceuticals, Inc. Earnings Q2, 2015 Aug 26 2015
AMAG is a Hidden Biotech Gem That is Exploding Aug 25 2015
AMAG Pharmaceuticals Appoints Joseph Vittiglio as General Counsel and Secretary Aug 24 2015
AMAG Pharmaceuticals Appoints Joseph Vittiglio as General Counsel and Secretary Aug 24 2015
Why Biotech AMAG Pharma Is Worth $80 Now Aug 18 2015
Should AMAG Pharmaceuticals (AMAG) Be On Your Radar Now? Aug 18 2015
What the Cord Blood Registry Buyout Really Adds to AMAG Aug 17 2015
AMAG Pharmaceuticals Completes Acquisition of Cord Blood Registry Aug 17 2015
AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Aug 17 2015
AMAG Pharmaceuticals Completes Acquisition of Cord Blood Registry Aug 17 2015
VIVUS Inc. (VVUS) in Focus: Stock Jumps 5.4% Aug 13 2015
AMAG Pharmaceuticals Announces Pricing of Private Offering of $500 Million of Senior Notes Due 2023 Aug 12 2015
AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 12 2015
Pluristem (PSTI) Provides Update on PLX-PAD Cells in Japan Aug 12 2015
AMAG Pharmaceuticals Announces Pricing of Private Offering of $500 Million of Senior Notes Due 2023 Aug 12 2015
BioScrip's Strategic Plans Offer Hope, Margin Concerns Stay Aug 12 2015
Merrimack Pharmaceuticals (MACK) Catches Eye: Stock Up 5.8% Aug 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK